Biophysicists at Emory University published a study in Nature Communications on July 20, 2026, revealing that muscle actin filaments can grow from their pointed minus ends, overturning a 40-year-old scientific dogma. Led by Shashank Shekhar and PhD candidate Sudipta Biswas, the research demonstrated that the protein leiomodin 2 acts as a processive pointed-end elongator, solving the long-standing paradox of how muscle sarcomeres maintain fixed lengths while continuously replacing aging proteins. The authors emphasize that while actin filaments in muscle sarcomeres maintain strict overall length control during constant protein turnover, they defy the traditional treadmilling model where growth happens exclusively at barbed plus ends. By utilizing microfluidic-assisted total internal reflection fluorescence microscopy mf-TIRF, the team visually tracked individual protein assemblies to prove that new actin subunits attach at the pointed ends anchored by leiomodin 2. This fundamental cellular discovery explains the precise structural maintenance of heart and skeletal muscle cytoskeletons. Furthermore, the findings provide a crucial molecular mechanism for understanding how genetic mutations in leiomodin 2 disrupt contractile machinery assembly, directly linking to human pathologies such as dilated cardiomyopathy, a leading cause of heart failure. The research opens new therapeutic pathways for diagnosing and treating genetic muscle disorders by clarifying how protein regulation affects filament length. Researchers can now target these specific elongation mechanisms to explore interventions for heart failure and other debilitating myopathies associated with cytoskeletal defects.
